Clinical Trial Update: A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis [Phase 1]

View source ↗

Summary

Phase I trial evaluating a single subcutaneous or intravenous dose of SHR-1139 in healthy Chinese subjects and multiple subcutaneous doses in patients with mode…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SHR-1139

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Moderate to Severe Plaque Psoriasis | Phase 1 | Status: COMPLETED